Company Tagline
Developing a new class of ADCs based on NMT inhibition to treat cancer
Industry Category
Business Keywords
Company Description
Myricx Bio is at the forefront of biotechnology research, dedicated to developing a novel class of Antibody Drug Conjugates (ADCs) for cancer treatment. Focusing on NMT inhibition, Myricx Bio is committed to innovation and the advancement of therapeutic solutions in oncology.
Located in London, at Kings Cross, Myricx Bio leverages cutting-edge research and development to create selective cytotoxic payloads. The company's approach aims to provide more effective and targeted cancer therapies, contributing significantly to the field of biotechnology.
Myricx Bio is dedicated to pushing the boundaries of scientific discovery and improving patient outcomes. We invite the management team at Myricx Bio to enhance this profile further by creating a customized company showcase and product listing on our platform, highlighting the unique aspects of their work.
Key Personnel / Employees
Similar Companies
Other organizations in the same industry
AgenT
Biotechnology-ResearchDetect Alzheimer's earlier, when it could be prevented
Neurotrack
Biotechnology-ResearchWe partner with healthcare providers and payers to optimize cognitive screening workflows with effic...
Persea
Biotechnology-ResearchThe next generation treatment changing the game against solid cancers, after ADCs.
Alternative Company Names
This company is also known as